Early treatment resistance in a Latin-American cohort of patients with schizophrenia

Simple item page
dc.contributor.authorMena, Cristian
dc.contributor.authorGonzález-Valderrama, Alfonso
dc.contributor.authorIruretagoyena, Bárbara
dc.contributor.authorUndurraga, Juan
dc.date.accessioned2022-05-24T21:35:02Z
dc.date.available2022-05-24T21:35:02Z
dc.date.issued2018
dc.description.abstractBackground: Failure to respond to antipsychotic medication in schizophrenia is a common clinical scenario with significant morbidity. Recent studies have highlighted that many patients present treatment-resistance from disease onset. We here present an analysis of clozapine prescription patterns, used as a real-world proxy marker for treatment-resistance, in a cohort of 1195 patients with schizophrenia from a Latin-American cohort, to explore the timing of emergence of treatment resistance and possible subgroup differences. Methods: Survival analysis from national databases of clozapine monitoring system, national disease notification registers, and discharges from an early intervention ward. Results: Echoing previous studies, we found that around 1 in 5 patients diagnosed with schizophrenia were eventually prescribed clozapine, with an over-representation of males and those with a younger onset of psychosis. The annual probability of being prescribed clozapine was highest within the first year (probability of 0.11, 95% confidence interval of 0.093-0.13), compared to 0.018 (0.012-0.024) between years 1 and 5, and 0.006 (0-0.019) after 5years. Age at psychosis onset, gender, dose of clozapine used, and compliance with hematological monitoring at 12months, was not related to the onset of treatment resistance. A similar pattern was observed in a subgroup of 230 patients discharged from an early intervention ward with a diagnosis of non-affective first episode of psychosis. Conclusions: Our results highlight that treatment resistance is frequently present from the onset of psychosis. Future studies will shed light on the possible different clinical and neurobiological characteristics of this subtype of psychosis.es
dc.description.versionVersión Publicadaes
dc.identifier.citationMena C, Gonzalez-Valderrama A, Iruretagoyena B, Undurraga J, Crossley NA. Early treatment resistance in a Latin-American cohort of patients with schizophrenia. Schizophr Res. 2018 Sep;199:380-385. doi: 10.1016/j.schres.2018.02.056.es
dc.identifier.urihttps://doi.org/10.1016/j.schres.2018.02.056es
dc.identifier.urihttp://hdl.handle.net/11447/6134
dc.language.isoenes
dc.relation.projectThis study was partly supported by the Chilean National Corporation for Science and Technology CONICYT through an Interdisciplinary Research Programme grant PIA ACT1414; FONDECYT Regular 1160736 (to NAC) and FONDECYT Regular 1180358 (to JU); a research grant from Clínica Alemana de Santiago (to JU); and a grant from Universidad Finis Terrae (to AGV)es
dc.subjectClozapinees
dc.subjectSchizophreniaes
dc.subjectTreatment-resistancees
dc.titleEarly treatment resistance in a Latin-American cohort of patients with schizophreniaes
dc.typeArticlees
dcterms.sourceSchizophrenia Researches

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
1-s2.0-S0920996418301361-main.pdf
Size:
641.31 KB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services